Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma.
Journal: Expert opinion on biological therapy
Published: May 13, 2024
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
Journal: The New England journal of medicine
Published: June 05, 2023
BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma.
Journal: Journal for immunotherapy of cancer
Published: March 30, 2023
Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study.
Journal: Clinical lymphoma, myeloma & leukemia
Published: March 21, 2023
Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma.
Journal: Oncology and therapy
Published: January 25, 2023
Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Journal: Current medical research and opinion
Published: October 22, 2022
Recent Advances in the Use of Chimeric Antigen Receptor-Expressing T-Cell Therapies for Treatment of Multiple Myeloma.
Journal: Clinical lymphoma, myeloma & leukemia
Published: June 07, 2022
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 06, 2022
Population-based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myeloma.
Journal: Clinical and translational science
Published: June 02, 2022
Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study.
Journal: Clinical lymphoma, myeloma & leukemia
Published: May 24, 2022
Process, resource and success factors associated with chimeric antigen receptor T-cell therapy for multiple myeloma.
Journal: Future oncology (London, England)
Published: May 18, 2022
Comprehensive BCMA Expression Profiling in Adult Normal Human Brain Suggests a Low Risk of On-target Neurotoxicity in BCMA-targeting Multiple Myeloma Therapy.
Journal: The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
Published: February 23, 2022
Last Updated: 09/26/2026